Blog

In a groundbreaking collaboration between the legendary Bob Marley and Keepsake Trading Cards, fans are invited to experience the legacy of a musical icon through a unique, high-end trading card set designed to capture the spirit and history of Bob Marley.

LOS ANGELES, CA / ACCESS Newswire / July 23, 2025 / In a groundbreaking collaboration between the legendary Bob Marley and Keepsake Trading Cards, fans are invited to experience the legacy of a musical icon through a unique, high-end trading card set designed to capture the spirit and history of Bob Marley. This exclusive collection is set to launch on September 17th, 2025, making it a must-have for both music enthusiasts and collectors alike.

The Bob Marley Keepsake Premiere Edition promises an array of rare and authentic memorabilia to celebrate the life and enduring influence of the reggae legend.

Each box, priced at $59.95, includes:

• 1 Memorabilia Relic Card & 8 Five-Card Packs: Featuring precious items such as a personal signature from Bob Marley, authentic handwriting, unique artifacts like a personal tour-used piano, original ticket stubs, and more amazing artifacts.

This partnership reflects a shared commitment to preserving and celebrating the cultural impact of Bob Marley’s music and message. Collectors and fans will have the opportunity to own a tangible piece of Marley’s legacy.

“Daddy poured so much love and purpose into everything he did, and it means a lot to see pieces of his journey shared this way,” said Cedella Marley. “This project with Keepsake is really special-it gives fans a chance to hold a part of his story, to feel closer to the energy and message he carried through his music and his life.”

Keepsake Trading Cards, known for their innovation and quality in the collectible industry, is proud to pay tribute to one of the greatest musicians of all time. “We wanted to create something truly special that allows fans to celebrate and connect with the profound artistry of Bob Marley,” said Scott Allen for Keepsake Trading Cards. “This collection is a testament to his enduring legacy and universal appeal.”

Available in select retail outlets and online, the Bob Marley Keepsake Trading Card Set is set for a September 17th, 2025 release. Fans are encouraged to secure their collection early to avoid missing out on this exclusive offering.

For more information on purchasing and availability, please visit www.keepsaketradingcards.com or contact Mathew Ezer at Mathew@superproductscorporation.com.

ABOUT BOB MARLEY

Bob Marley is not only the man who put Reggae on the global map but a peacemaker and statesman in his native Jamaica, bringing together the country’s warring factions. Today, Marley remains one of the 21st century’s most important and influential entertainment icons – a symbol of unity – with his music and lifestyle having an indelible impact on new generations of fans globally. His legacy lives on through his lyrics, songs and call to action.

The 2024 biographical drama and musical film, Bob Marley: One Love, opened at No. 1 in 13 major markets, including the U.S, U.K., France, Australia, Netherlands, New Zealand, Portugal, and Norway. The movie set box office records during its release, surpassing the $200 million mark and solidifying its place as a cultural and cinematic phenomenon.

In the digital era, he has the second-highest social media following of any posthumous celebrity with more than 66 million Facebook fans. Marley’s music catalog has sold millions of albums worldwide. His iconic collection LEGEND is the longest-charting album in BillboardMagazine’s Catalog Albums chart and remains the world’s best-selling reggae album and second longest charting album of all time overall. “Three Little Birds” and “Could You Be Loved” have both surpassed one billion streams on Spotify, making him the first reggae act with two solo songs to reach this milestone.

Bob Marley’s legacy has been cemented with numerous awards and honors, including his posthumous induction into the Rock and Roll Hall of Fame in 1994, a Grammy Lifetime Achievement Award in 2001, and Jamaica’s Order Of Merit, recognizing his profound impact on music and culture worldwide. Marley’s music continues to be recognized, as a newly recorded collection of his songs recently won the 2025 Grammy for Best Reggae Album.

From his first album to every new release, his music and influence continue to be an integral part of each generation’s playlist.

For more information, visit bobmarley.com and on all social platforms @bobmarley.

ABOUT KEEPSAKE TRADING CARDS

Keepsake Trading Cards is renowned for their exceptional quality and innovative designs. Specializing in creating unique and memorable trading cards, Keepsake takes pride in celebrating icons and exceptional moments in history for music, pop culture, and entertainment.

For more information, visit keepsaketradingcards.com and on all social platforms @keepsaketradingcards

Media Contact:

Mathew Ezer
Marketing
Keepsake Trading Cards
mathew@superproductscorporation.com
310-755-9955

Scott Allen
Co-Founder
superbreaksports@gmail.com
(310)-755-9955

SOURCE: Super Products Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / July 23, 2025 / Freedom Holding Corp., a NASDAQ-listed global financial services and technology company, is honored to sponsor the upcoming 2025 FIDE World Schools Team Championship and the Smart Moves Summit. The championship will be held August 3-6, 2025, and the summit will take place August 4-5, 2025,at Episcopal High School in Alexandria, in the Washington, D.C. area.

These events will bring together young, talented chess players from 47 countries, as well as leading figures in education, technology, and innovation. It is the first time that school chess teams will compete in the U.S. capital.

Timur Turlov, founder and CEO of Freedom Holding, also serves as the head of the International School Chess Federation (ISCF). Motivated by a passion for the game, he is dedicated to nurturing and supporting young chess players around the world.

“Behind every young chess player is a story of effort and curiosity. Though they come from different countries, they share a love for learning, strategy, and challenge. We believe these stories deserve a global stage. Supporting the FIDE World Schools Team Championship and the Smart MovesSummit creates space for youngminds to connect,grow, and be seen. At Freedom Holding, we’re proud to stand behind institutions that open opportunities for the next generation,” says Timur Turlov.

We invite media representatives to join us in covering this truly global gathering. The championship will feature exciting contests between some of the world’s most gifted young players. Meanwhile, the summit will provide a platform for in-depth discussions and fresh perspectives on how strategic thinking and innovation can shape the future.

Apply for media accreditation by sending an email to prglobal@ffin.kz to gain exclusiveaccess to:

• Interviews with players, coaches, and thought leaders

• Key championship rounds and awardceremonies

• Expertpanels and keynotesessions at the Smart Moves Summit

The founder of Freedom Holding, Timur Turlov, may also be available for interviews.

Learn more about these events:

Championship website: https://worldschoolteam2025.fide.com/

Smart Moves Summit: https://worldschoolteam2025.fide.com/summit/

For accreditation, pleasecontact us at: prglobal@ffin.kz

About Freedom Holding Corp.

Freedom Holding Corp. provides financial services in 22 countries, including Kazakhstan, the United States, Cyprus, Poland, Spain, Uzbekistan, and Armenia. The Company’s executive headquarters is located in New York City.

In Kazakhstan, Freedom is actively developing its financial and digital ecosystem, which includes Freedom Bank, Freedom Broker, the insurance companies Freedom Life and Freedom Insurance, as well as a lifestyle segment that features Arbuz.kz, Freedom Ticketon, and Aviata.

Freedom Holding Corp. shares are traded on the U.S. technology exchange NASDAQ, the Kazakhstan Stock Exchange (KASE),and the Astana International Exchange(AIX) under the ticker symbol FRHC. The Company has a market capitalization exceeding $8 billion as of March 31, 2025. Freedom Holding Corp. is regulated by the U.S. Securities and Exchange Commission (SEC).

SOURCE: Freedom Holding Corp.

View the original press release on ACCESS Newswire

NSPA Supports Denmark and European Countries in MQ-9B Acquisition and Sustainment

SAN DIEGO, CA / ACCESS Newswire / July 23, 2025 / Denmark and the NATO Support and Procurement Agency (NSPA) have announced the procurement of four MQ-9B SkyGuardian^® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. The purchase includes three Certified Ground Control Stations.

Denmark joins a growing list of European countries that have selected MQ-9B for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in the harsh conditions of the Arctic in support of Denmark and its NATO Allies. Additionally, MQ-9B’s in-house-developed Detect and Avoid System aids MQ-9B’s ability to fly in unsegregated airspace for domestic civilian operations, making it highly versatile for operations from Denmark.

MQ-9B recently became the first large remotely piloted aircraft to obtain a Military Type Certificate (MTC) from the UK’s Military Aviation Authority, certifying its safe operation without geographic restrictions, including over populous areas.

“It’s been a very productive year for our MQ-9B platforms,” said GA-ASI President David R. Alexander. “First, we earned MTC and now we’ve added Denmark to the U.K., Belgium, and Poland as MQ-9B customers in Europe. I believe the extensive waters of the North Sea, Norwegian Sea, and Baltic Sea of the Nordic countries make the MQ-9B a very effective tool for national maritime surveillance and security.”

MQ-9B SkyGuardian is the first and only unmanned system to offer multi-domain Intelligence, Surveillance, Reconnaissance, and Targeting (ISR&T) as an internal payload that can search the ocean’s surface and its depths in support of Fleet Operations. MQ-9B can also be fitted with a number of payloads including a maritime surveillance package with a 360-degree maritime radar and/or sonobuoy dispensing pods.

This sale was aided and supported by NSPA, which has developed a contractual framework for supporting cooperation amongst its member nations and promoting the proliferation of MQ-9B in Europe. NSPA has added MQ-9B to its portfolio of defense systems to contract on behalf of European nations, with the goal of enhancing interoperability while facilitating training and joint operations.

“This procurement demonstrates how NSPA enables efficient, effective and responsive multinational acquisitions for advanced, interoperable capabilities. We are proud to support Denmark in this strategic investment for national maritime surveillance and security,” said Ms. Stacy A. Cummings, NSPA General Manager.

About GA-ASI

General Atomics Aeronautical Systems, Inc. is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator^® line of UAS has flown for over 30 years and includes MQ-9A Reaper^®, MQ-1C Gray Eagle^®, MQ-20 Avenger^®, and MQ-9B SkyGuardian^®/SeaGuardian^®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.

For more information, visit www.ga-asi.com.

Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.

# # #

Contact Information

GA-ASI Media Relations
asi-mediarelations@ga-asi.com
(858) 524-8101

SOURCE: General Atomics Aeronautical Systems, Inc.

Related Images

View the original press release on ACCESS Newswire

Live Coaching to Help Retirees Turn Savings into Lifetime Paychecks

JACKSONVILLE, OR / ACCESS Newswire / July 23, 2025 / Retirement income expert Cathy Mendell, founder of Theia Financial, is launching Your Next Chapter, a highly interactive live virtual coaching workshop created to guide retirees through their transition from work paychecks to retirement paychecks. With coaching workshops for the public and private retirement readiness workshops designed for employers, Your Next Chapter provides those nearing retirement with a guided path to the vital components of creating a successful retirement income plan.

The massive wave of Americans approaching retirement, who are the first to rely on 401(k)s and other defined contribution plans rather than traditional pensions, now faces a critical turning point. The shift from relying on employer-managed retirement plans to the sudden responsibility of self-managing their investments upon leaving the workforce has many retirees feeling uncertain, vulnerable to market risk, and overwhelmed as they realize the onus has been placed on them to convert their retirement assets into a reliable monthly income that they won’t outlive. With 11,200 Americans turning 65 every day through 2027, the need for guidance has never been greater.

Cathy Mendell has provided one-on-one coaching to hundreds of retirees as they transition from the accumulation phase of retirement, while working, to the decumulation phase upon retirement. With her proprietary framework, TheiaPath, she offers more than just a “probability of success”; she delivers a step-by-step process to help clients maximize their monthly retirement income and protect themselves against the financial threats of longevity, inflation, taxes, and sequence-of-returns risk in the stock market.

Through Your Next Chapter, Mendell now opens up the TheiaPath framework in the form of group coaching workshops where participants can engage, ask questions, and get answers in real-time. Here, they will define retirement goals, map out lifestyle expenses, learn about withdrawal tax strategies, discover guaranteed income options, and begin to build a retirement paycheck plan they can count on for life.

“Too many retirees are stuck hoping their savings will last, with no clear plan or income strategy. Your Next Chapter changes that. This is more than coaching, it’s a lifeline,” said Cathy Mendell, Founder of Theia Financial. “I created this program to give everyday Americans access to the information they need to begin creating a clear path to predictable income, peace of mind, and a retirement they can actually enjoy.”

About Cathy Mendell & Theia Financial:

Cathy Mendell is a nationally recognized retirement income strategist and the founder of Theia Financial. Known for her holistic and personalized approach, Cathy has helped hundreds of individuals navigate the complex transition from saving to generating reliable retirement income. Her proprietary framework, TheiaPath, offers clients a 7-step process and a written blueprint for securing a guaranteed lifetime income, enabling them to retire with clarity, security, and peace of mind.

Theia Financial is built on the belief that trust, transparency, and education are non-negotiables in financial planning. Beyond her financial work, Cathy is also deeply committed to global philanthropic efforts, including her support of the Orphanages of Kenya initiative. Her mantra reflects her mission: “Without reliable lifetime income, there is no retirement.” For more information, visit https://yournextchapterworkshop.com

Press Contact:

Veronica Welch
VEW Media
ronnie@vewpr.com
508-643-8000

SOURCE: Cathy Mendell – Theia Financial

View the original press release on ACCESS Newswire

FREMONT, CA / ACCESS Newswire / July 23, 2025 / Exclusive Networks, a global leader in cybersecurity, has established a North American distribution agreement with A10 Networks that will magnify the reach of the distributor’s security and infrastructure solutions for on-premises, hybrid cloud and edge-cloud environments.

“We place a high value on organizations that can effectively support our missions in both cybersecurity and the channel, and Exclusive Networks excels in both areas,” says Phil Labas, RVP, Americas channel and alliance partners at A10 Networks. “This relationship will expand our reseller base, education and marketing abilities, and collective technical expertise, as well as support strategic use cases in security and AI across the enterprise market.”

This new arrangement allows solution providers to procure A10 Networks’ products and services in the United States and Canada through the Exclusive Networks’ growing community. A10’s specialized network, application and AI security solutions target mid-market to enterprise organizations, including global enterprises, service providers, federal agencies, and public sector institutions. The A10 Networks solutions are designed to support customers with complex networking, security, and application delivery requirements-such as DDoS protection, SSL inspection, CGNAT, NG-WAF, API and bot protection, and AI-ready high-performance load balancing.

“MSPs, VARs, solution providers and systems integrators are seeking more advanced cybersecurity tools to protect their clients and themselves from the rising threats, and our new relationship with A10 Networks will simplify that process,” says Andrew Warren, Vice President of Sales & Marketing for Exclusive Networks, North America. “This agreement is consistent with our commitment to offering the most comprehensive network, application and AI security solutions to our partners and, ultimately, their clients. We anticipate A10 Networks will bring a wealth of new sales and support opportunities to all the skilled IT and cybersecurity professionals in the Exclusive Networks community.”

Key advantages of this agreement for the community include:

• More advanced and highly comprehensive network, application and AI security capabilities

• Simplified procurement through Exclusive Networks

The addition of A10 Networks to Exclusive Networks’ line card is part of a larger initiative to expand the distributor’s capabilities and presence in North America. This includes major additions to its North American leadership team, and revitalized investments in consultative services and offerings that go beyond traditional legacy distribution offerings. The objective is to support resellers and end users in the most practical and urgent ways possible, helping them grow and thrive.

For more information or help ordering these technologies, contact your Exclusive Networks North American account management team.

About Exclusive Networks
Exclusive Networks is a global cybersecurity go-to-market specialist that provides partners and end-customers with a wide range of services and product portfolios via proven routes to market. With offices in over 45 countries and the ability to serve customers in over 170 countries, we combine a local perspective with the scale and delivery of a single global organization.

Our best-in-class vendor portfolio is carefully curated with all leading industry players. Our services range from managed security to specialist technical accreditation and training and capitalize on rapidly evolving technologies and changing business models. For more information visit https://www.exclusive-networks.com/usa/.

# # #

The A10 logo and A10 Networks are trademarks or registered trademarks of A10 Networks, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

FOR MORE INFORMATION, CONTACT:
Suzanne Mattaboni, CommCentric (on behalf of Exclusive Networks)
smattaboni@commcentric.com

SOURCE: Exclusive Networks USA

View the original press release on ACCESS Newswire

BATON ROUGE, LA / ACCESS Newswire / July 23, 2025 / Vista Consulting has officially unveiled Vista Institute, a groundbreaking online education platform designed exclusively for plaintiff law firms. This innovative platform addresses a critical need for on-demand, customized learning that helps law firms optimize operations, enhance team performance, and drive growth.

The launch comes after decades of observing significant gaps in the marketplace for tailored legal education. Many small to mid-sized plaintiff law firms struggle to access industry-specific resources that support continuing education and operational improvement. Vista recognized this challenge and set out to create a solution that combines flexibility, expertise, and transformative insights.

“Our work with firms revealed a common theme,” said Mary Ellen Murrah, Chief Strategy & Marketing Officer of Vista Consulting. “Plaintiff law firms need education resources that are practical, relevant, and adaptable to their unique challenges. Vista Institute is our answer to this demand: a platform built to empower firms to thrive in an increasingly competitive industry.”

Custom Learning, Anytime and Anywhere
Unlike traditional training programs, Vista Institute delivers a fully customizable learning experience. The platform offers a wide range of courses designed to tackle critical areas for plaintiff law firms such as client intake, case management, reporting, leadership, and marketing. Firms can access content on-demand, allowing team members to learn at their own pace and test their knowledge without disrupting daily operations.

Key features include:

• Expert-led video courses and modules.

• Downloadable resources and role-specific training paths.

• Interactive quizzes to reinforce learning.

Increasing Efficiency and Driving Results
At its core, Vista Institute is a business growth tool. Each course is designed to deliver strategies that lead to measurable outcomes. For example, firms looking to improve their intake process can follow step-by-step guidance to optimize lead conversion, while leadership courses focus on building stronger, more cohesive teams.

Early adopters of the platform have reported noticeable improvements. Tina Jones, Office Manager and Marketing Director for Long & Long Attorneys, said, “Vista Institute has been my ultimate survival guide. Having their expert knowledge at my fingertips has completely transformed how I lead my law firm. From accounting and HR to data analysis and talent acquisition, every critical piece of running a successful practice is just a click away. The post-presentation Q&As are pure gold, providing actionable insights I can implement immediately. Thanks to Vista Institute, I’ve not only streamlined my operations, but also elevated my ability to lead with confidence and clarity. It’s like having the ultimate roadmap to managing a thriving plaintiff law firm.”

Transforming the Education Landscape for Law Firms
The introduction of Vista Institute marks a shift in how plaintiff law firms approach continuing education. By offering a platform that emphasizes customization, accessibility, and measurable results, Vista aims to set a new standard in the legal industry.

“Law firms need more than generic advice and outdated training tools,” added Vista’s CEO Tim McKey. “They need resources that reflect the unique dynamics of plaintiff law practice. Vista Institute delivers exactly that.”

About Vista Consulting
Vista Consulting specializes in helping plaintiff law firms optimize their operations and achieve greater success. With decades of industry experience, Vista has become a trusted partner for firms seeking data-driven solutions and practical operations guidance.

For more information about Vista Institute and how to get started, visit https://vistainstitute.vistact.com/

SOURCE: Vista Consulting Team

View the original press release on ACCESS Newswire

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date

FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute (“TSRI”) to advance the development of the Company’s development program evaluating the combination of systemic DNase I and CAR T-cell therapies.

Xenetic’s systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy. Importantly, systemic DNase I-mediated degrading of neutrophil extracellular traps (NETs) enhances CAR-T cell efficacy increasing the infiltration of both CAR-T cells and endogenous T cells into tumors and by mitigating the immunosuppressive tumor microenvironment (TME). Based on these promising results, the research program has been expanded to include additional models of lymphoma and leukemia to further validate these findings.

“We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform. The data generated to date continues to be encouraging and we believe provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy. We are grateful for the Scripps Research team and look forward to continuing to leverage their knowledge and expertise,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Xenetic’s DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, thereby promoting cancer spread and local and systemic immunosuppression. Reduction of NETs burden via application of Xenetic’s proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models.

Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, “making”, and other words of similar meaning, including, but not limited to: continuing to leverage the knowledge and expertise of the team at Scripps to potentially expand and broaden the utility of our proprietary platform technology; and expectations regarding our DNase-based oncology platform, including statements regarding: advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications; focusing on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications; advancing the development of the Company’s program on the combination of systemic DNase and CAR T-cell therapies; our belief that preclinical data that highlights the critical role of NETs in modulating CAR-T cell efficacy provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy; plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors; the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression; and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. All forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.

As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.

Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.

Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).

To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox ^[1] . There is no effective drug for MPox at present.

Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon ^[1] .

Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.

We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.

The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.

The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.

Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses ^[2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.

To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.

Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.

NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

^[1] Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox therapeutics based on animal model data generated in animal infections by animal native orthpoxviruses. Tecovirimat failed in clinical trials of MPox. Brincidofovir caused sever drug-induced liver injury (DILI) in there of three patients given the drug in case studies, not in clinical trial.

^[2] It has been reported that highly pathogenic duck influenza viruses that lack or substantially lack HSPG binding ability do not cause significant pathology in other birds, nor in humans. They appear to use exclusively sialic acid-related receptors and yet have failed to infect other species. We believe these results require further investigation.

SOURCE: NanoViricides

View the original press release on ACCESS Newswire